Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer

clinical trial

Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT00118261

P6099clinical trial phasephase I clinical trialQ5452194
P17countryUnited States of AmericaQ30
P582end time2011-01-01
P2899minimum age18
P1132number of participants17
P4844research interventionleucovorin calciumQ27077063
fluorouracilQ238512
calcium oxalateQ412399
bevacizumabQ413299
P6153research siteMetroHealth Medical CenterQ30254005
Case Western Reserve UniversityQ1047060
P859sponsorCase Comprehensive Cancer CenterQ39050124
P580start time2005-03-01
P8363study typeinterventional studyQ78089383
P1476titleA Phase IB Study in Patients With Metastatic Colorectal Cancer to Evaluate Pharmacodynamic Effects of Erlotinib and Safety and Efficacy of Erlotinib in Combination With Modified FOLFOX6 (mFOLFOX6) and Bevacizumab

Search more.